Merus N.V. – NASDAQ:MRUS
Merus N.V. stock price today
$64.23
+22.16
+52.67%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Merus N.V. stock price monthly change
-26.53%
month
Merus N.V. stock price quarterly change
-26.53%
quarter
Merus N.V. stock price yearly change
+47.25%
year
Merus N.V. key metrics
Market Cap | 2.88B |
Enterprise value | 585.74M |
P/E | -6.58 |
EV/Sales | 14.19 |
EV/EBITDA | -12.71 |
Price/Sales | 17.73 |
Price/Book | 2.96 |
PEG ratio | -0.06 |
EPS | -2.72 |
Revenue | 38.33M |
EBITDA | -148.78M |
Income | -149.65M |
Revenue Q/Q | -41.55% |
Revenue Y/Y | -11.72% |
Profit margin | -119.3% |
Oper. margin | -257.82% |
Gross margin | 0% |
EBIT margin | -257.82% |
EBITDA margin | -388.09% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMerus N.V. stock price history
Merus N.V. stock forecast
Merus N.V. financial statements
Average Price Target
$81.25
Potential upside: 26.49%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 10.47M | -32.03M | -305.78% |
|---|---|---|---|
| Sep 2023 | 11.03M | -23.01M | -208.57% |
| Dec 2023 | 8.93M | -60.15M | -672.93% |
| Mar 2024 | 7.88M | -34.45M | -436.76% |
| Jun 2023 | 363624000 | 106.21M | 29.21% |
|---|---|---|---|
| Sep 2023 | 492186000 | 98.79M | 20.07% |
| Dec 2023 | 458494000 | 102.15M | 22.28% |
| Mar 2024 | 498083000 | 148.63M | 29.84% |
| Jun 2023 | -41.58M | -24.51M | 65.96M |
|---|---|---|---|
| Sep 2023 | -27.53M | 8.02M | 162.40M |
| Dec 2023 | -34.88M | -1.80M | -1.24M |
| Mar 2024 | -44.38M | -12.07M | 30.15M |
Merus N.V. alternative data
| Aug 2023 | 164 |
|---|---|
| Sep 2023 | 164 |
| Oct 2023 | 164 |
| Nov 2023 | 164 |
| Dec 2023 | 164 |
| Jan 2024 | 164 |
| Feb 2024 | 164 |
| Mar 2024 | 172 |
| Apr 2024 | 172 |
| May 2024 | 172 |
| Jun 2024 | 172 |
| Jul 2024 | 172 |
Merus N.V. other data
0.03%
-79.22%
of MRUS is owned by hedge funds
41
-49
12.02M
-24.47M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 23326 |
| Jun 2024 | 0 | 86300 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | SILVERMAN PETER B. officer: COO & GC | Common Shares | 7,453 | $17.94 | $133,707 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Common Shares | 2,547 | $17.94 | $45,693 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Share Option (right to buy) | 7,453 | $17.94 | $133,707 | ||
Sale | SILVERMAN PETER B. officer: COO & GC | Common Shares | 10,000 | $60 | $600,000 | ||
Sale | SILVERMAN PETER B. officer: COO & GC | Common Shares | 62,000 | $56.52 | $3,504,178 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Common Shares | 9,253 | $17.94 | $165,999 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Common Shares | 2,747 | $17.94 | $49,281 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Common Shares | 41,577 | $25.9 | $1,076,844 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Common Shares | 8,423 | $25.9 | $218,156 | ||
Option | SILVERMAN PETER B. officer: COO & GC | Share Option (right to buy) | 9,253 | $17.94 | $165,999 |
Merus: Riding The Bispecific Wave In Oncology
Time To Upgrade Merus N.V. To A 'Buy' After The Recent Selloff
Biotech Stocks 2024 Second Half Outlook - Buy Biotechs
Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)
Merus: (Maybe) Building A Better Bispecific
Merus: Petosemtamab And Zeno The Driving Forces Behind Investment Returns
Merus: Dutch Drug Developer With An Interesting Platform
Marketplace Roundtable - Part 6 - Biotech And Healthcare
Merus: Precision Oncology Pioneer Continues To Execute In The Clinic
-
What's the price of Merus N.V. stock today?
One share of Merus N.V. stock can currently be purchased for approximately $64.23.
-
When is Merus N.V.'s next earnings date?
Unfortunately, Merus N.V.'s (MRUS) next earnings date is currently unknown.
-
Does Merus N.V. pay dividends?
No, Merus N.V. does not pay dividends.
-
How much money does Merus N.V. make?
Merus N.V. has a market capitalization of 2.88B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 5.68% to 43.95M US dollars.
-
What is Merus N.V.'s stock symbol?
Merus N.V. is traded on the NASDAQ under the ticker symbol "MRUS".
-
What is Merus N.V.'s primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Merus N.V.?
Shares of Merus N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Merus N.V.'s key executives?
Merus N.V.'s management team includes the following people:
- Dr. Sven Ante Lundberg Chief Executive Officer, Pres, Principal Financial Officer & Executive Director(age: 62, pay: $986,820)
- Mr. Peter B. Silverman J.D. Executive Vice President, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal(age: 47, pay: $614,880)
- Mr. Hui Liu Chief Bus. Officer, Executive Vice President & Head of Merus U.S.(age: 58, pay: $611,310)
-
How many employees does Merus N.V. have?
As Jul 2024, Merus N.V. employs 172 workers.
-
When Merus N.V. went public?
Merus N.V. is publicly traded company for more then 9 years since IPO on 19 May 2016.
-
What is Merus N.V.'s official website?
The official website for Merus N.V. is merus.nl.
-
How can i contact Merus N.V.?
Merus N.V. can be reached via phone at +31 30 253 8800.
-
What is Merus N.V. stock forecast & price target?
Based on 4 Wall Street analysts` predicted price targets for Merus N.V. in the last 12 months, the avarage price target is $81.25. The average price target represents a 26.49% change from the last price of $64.23.
Merus N.V. company profile:
Merus N.V.
merus.nlExchange:
NASDAQ
Full time employees:
172
Industry:
Biotechnology
Sector:
Healthcare
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Yalelaan 62
Utrecht, 3584 CM
Utrecht, 3584 CM
CIK: 0001651311
ISIN: NL0011606264
CUSIP: N5749R100
